Literature DB >> 32563763

Engineering microbial diagnostics and therapeutics with smart control.

Matthew B Amrofell1, Austin G Rottinghaus1, Tae Seok Moon2.   

Abstract

Microbes have become an increasingly powerful chassis for developing diagnostic and therapeutic technologies. While many of the earlier engineering efforts used microbes that expressed relevant proteins constitutively, more microbes are being engineered to express them with region-selectivity and disease-responsiveness through biosensors. Such 'smart' microbes have been developed to diagnose and treat a wide range of disorders and diseases, including bacterial infections, cancers, inflammatory disorders, and metabolic disorders. In this review, we discuss synthetic biology technologies that have been applied to engineer microbes for biomedical applications, focusing on recent reports that demonstrate microbial sensing by using animal models or clinical samples. Advances in synthetic biology will enable engineered microbes to significantly improve the medical field.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2020        PMID: 32563763      PMCID: PMC7744387          DOI: 10.1016/j.copbio.2020.05.006

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN: 0958-1669            Impact factor:   9.740


  54 in total

1.  A microbial endocrinology-based simulated small intestinal medium for the evaluation of neurochemical production by gut microbiota.

Authors:  Daniel N Villageliú; Sharon Rasmussen; Mark Lyte
Journal:  FEMS Microbiol Ecol       Date:  2018-07-01       Impact factor: 4.194

Review 2.  Synthetic biology moving into the clinic.

Authors:  Warren C Ruder; Ting Lu; James J Collins
Journal:  Science       Date:  2011-09-02       Impact factor: 47.728

3.  Enabling complex genetic circuits to respond to extrinsic environmental signals.

Authors:  Allison Hoynes-O'Connor; Tatenda Shopera; Kristina Hinman; John Philip Creamer; Tae Seok Moon
Journal:  Biotechnol Bioeng       Date:  2017-03-20       Impact factor: 4.530

Review 4.  Engineering bacteria for diagnostic and therapeutic applications.

Authors:  David T Riglar; Pamela A Silver
Journal:  Nat Rev Microbiol       Date:  2018-02-05       Impact factor: 60.633

5.  Short hairpin RNA-expressing bacteria elicit RNA interference in mammals.

Authors:  Shuanglin Xiang; Johannes Fruehauf; Chiang J Li
Journal:  Nat Biotechnol       Date:  2006-05-14       Impact factor: 54.908

6.  Rapid screening of engineered microbial therapies in a 3D multicellular model.

Authors:  Tetsuhiro Harimoto; Zakary S Singer; Oscar S Velazquez; Joanna Zhang; Samuel Castro; Taylor E Hinchliffe; William Mather; Tal Danino
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-17       Impact factor: 11.205

7.  Improving tumor targeting and therapeutic potential of Salmonella VNP20009 by displaying cell surface CEA-specific antibodies.

Authors:  Michal Bereta; Andrew Hayhurst; Mariusz Gajda; Paulina Chorobik; Marta Targosz; Janusz Marcinkiewicz; Howard L Kaufman
Journal:  Vaccine       Date:  2007-03-22       Impact factor: 3.641

8.  Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo.

Authors:  K B Low; M Ittensohn; T Le; J Platt; S Sodi; M Amoss; O Ash; E Carmichael; A Chakraborty; J Fischer; S L Lin; X Luo; S I Miller; L Zheng; I King; J M Pawelek; D Bermudes
Journal:  Nat Biotechnol       Date:  1999-01       Impact factor: 54.908

9.  Acoustic reporter genes for noninvasive imaging of microorganisms in mammalian hosts.

Authors:  Raymond W Bourdeau; Audrey Lee-Gosselin; Anupama Lakshmanan; Arash Farhadi; Sripriya Ravindra Kumar; Suchita P Nety; Mikhail G Shapiro
Journal:  Nature       Date:  2018-01-03       Impact factor: 49.962

10.  RGD Peptide Cell-Surface Display Enhances the Targeting and Therapeutic Efficacy of Attenuated Salmonella-mediated Cancer Therapy.

Authors:  Seung-Hwan Park; Jin Hai Zheng; Vu Hong Nguyen; Sheng-Nan Jiang; Dong-Yeon Kim; Michael Szardenings; Jung Hyun Min; Yeongjin Hong; Hyon E Choy; Jung-Joon Min
Journal:  Theranostics       Date:  2016-06-20       Impact factor: 11.556

View more
  1 in total

1.  Construction of a sustainable 3-hydroxybutyrate-producing probiotic Escherichia coli for treatment of colitis.

Authors:  Xu Yan; Xin-Yi Liu; Dian Zhang; Yu-Dian Zhang; Zi-Hua Li; Xu Liu; Fuqing Wu; Guo-Qiang Chen
Journal:  Cell Mol Immunol       Date:  2021-09-03       Impact factor: 22.096

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.